Takeda Pharmaceutical Company Limited

Scholar Rock, Inc.

Dyax Corporation

Yung Chyung

Burt Adelman

Daniel J Sexton

Ryan Faucette

Christopher TenHoor

Jon A Kenniston

Adriana Donovan

Ryan Iarrobino

Joseph Biedenkapp

Andrew Nixon

Michelle Marie Straub

Jeffrey S Flier

Christopher Tenhoor

Stefan Wawersik

Gregory P Conley

Kimberly Kafadar Long

Christopher Chapron

Micah Webster

Greg Conley

Jennifer Schranz

George Nomikos

Guochen Song

Micah T Webster

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.

Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.

Compositions and methods for making and using anti-myostatin antibodies

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.

Use of myostatin inhibitors and combination therapies

Growing community of inventors

Lexington, MA, United States of America

Yung Chyung